Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 36%
Sell 7%
Strong Sell 0%

Bulls say

Incyte's stock outlook is bolstered by a significant year-over-year revenue growth, primarily driven by a 10% increase in Jakafi demand across its cancer indications, along with a strong commercial launch of Niktivmo. The company's adjustment of fiscal year 2025 guidance to a projected revenue range of $4.23B to $4.32B highlights their confidence in sustaining growth, particularly with Jakafi's updated revenue expectations of $3.05B to $3.075B. Additionally, the performance of Opzelura, which exceeded expectations with $188M in sales, underscores the expanding market potential in dermatology, reinforcing Incyte's diverse portfolio and growth trajectory.

Bears say

Incyte faces a challenging outlook primarily due to the erosion of pricing power for its leading drug, Jakafi, alongside poor performance anticipated from its earlier-stage pipeline. Significant risks include disruptions to its base business caused by poor uptake, reimbursement challenges, strong competition, and potential safety concerns regarding marketed products. The company may encounter further setbacks with its ongoing clinical trials, which could hinder the extension of Jakafi's life cycle and lead to greater-than-expected declines in sales growth.

Incyte (INCY) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 36% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 14 analysts, Incyte (INCY) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.